Trial Profile

Effect of Aumolertinib for Patients With EGFR mutated pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy/Radiotherapy

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aumolertinib (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

16 Sep 2022 Recruitment is likely to complete by 2023-02-18 as per the Chinese Clinical Trial Register record
16 Sep 2022 New trial record
09 Aug 2022 Study design presented at the 2022 World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com